214 related articles for article (PubMed ID: 15733113)
1. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Feb; 12(2):182-6. PubMed ID: 15733113
[TBL] [Abstract][Full Text] [Related]
2. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
3. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
4. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
5. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
6. The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy.
Winkler MH; Khan FA; Kulinskaya E; Hoh IM; McDonald D; Boustead G; Kaisary AV
BJU Int; 2004 Oct; 94(6):812-5. PubMed ID: 15476514
[TBL] [Abstract][Full Text] [Related]
7. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
10. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
11. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S
Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100
[TBL] [Abstract][Full Text] [Related]
12. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
[TBL] [Abstract][Full Text] [Related]
13. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
Custovic Z; Kraus O; Tomaskovic I; Tarle M
Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
[TBL] [Abstract][Full Text] [Related]
14. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
Pannek J; Rittenhouse HG; Chan DW; Epstein JI; Walsh PC; Partin AW
J Urol; 1998 Apr; 159(4):1238-42. PubMed ID: 9507844
[TBL] [Abstract][Full Text] [Related]
15. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
16. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
[TBL] [Abstract][Full Text] [Related]
17. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
18. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens.
Park EA; Lee HJ; Kim KG; Kim SH; Lee SE; Choe GY
Int J Urol; 2007 Aug; 14(8):704-8. PubMed ID: 17681059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
